0.30Open0.30Pre Close0 Volume1.16K Open Interest10.00Strike Price0.00Turnover235.09%IV104.37%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier26DDays to Expiry0.30Extrinsic Value100Contract SizeAmericanOptions Type0.2182Delta0.0935Gamma16.80Leverage Ratio-0.0181Theta0.0006Rho3.67Eff Leverage0.0040Vega
Candel Therapeutics Stock Discussion
5.30+
Now Let's Get That 10.+ Back!
Let's Get 5.+
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
Candel Therapeutics announced preclinical results for CAN-3110 in melanoma models, showing potential expansion beyond high-grade glioma treatment. CAN-3110, a first-in-class HSV-1 oncolytic viral immunotherapy, demonstrated potent antitumor activity in both in vitro human cel...
No comment yet